Ash 2022 – toxicity still looms large for Regeneron’s bispecific
Another five treatment-related deaths, despite a dose regimen change, raise questions about whether odronextamab will be able to compete.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
